

DAFTAR PUSTAKA

- Agustina, R., Windarti, I., Ramadhian, M.R., Rahmanisa, S., Kurniawaty, E. 2017. Hubungan Derajat Diferensiasi Histopatologik dengan Rekurensi Kanker Payudara di Rumah Sakit Umum Abdul Moeloek Bandar Lampung. *Majority*. Vol. 6(3) : 1-5.
- Al-Zawi, A. S. A., Syed A., Salih, A., Idaewor, P., Elamass, M., *et al.* 2021. Evaluation of the correlation between Ki-67 proliferative index and the histopathological grade of invasive neoplasms in early breast cancer aged < 70 years of age: a review of 300 cases. *Medical Research Journal*. Vol. 6(1):4-7. DOI : 10.5603/MRJ.a2020.0049
- Alco, G., Bozdogan, A., Selamoglu, D., Pilancı, K.N., Tuzlali, S., Ordu, C., *et al.* 2015. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. *Oncology Letters*. Vol. 9:1046-1054. <https://doi.org/10.3892/ol.2015.2852>
- Allain DC, Norwood Toro L, Oakley GM, Smolkin M, Osiowy C, Leitch AM, Hu JJ. 2021. Mutations in TP53 and BRCA1/2 are associated with high-grade luminal B breast cancer. *NPJ Breast Cancer*. Vol. 7(1):30.
- Andra, D. 2018. Hubungan Usia dengan Kejadian Kanker Payudara di Instalasi Patologi Anatomi RSUP Haji Adam Malik tahun 2014-2015. In *Skripsi*. Medan: Fakultas Kedokteran Universitas Sumatera Utara.
- ASCO (American Society of Clinical Oncology). 2020. Breast Cancer Molecular Subtypes: Overview. *Online*. <https://www.cancer.net/cancer-types/breast-cancer/molecular-subtypes> diakses tanggal 05 Mei 2023.
- Brunner & Suddarth. 2015. *Buku Ajar Keperawatan Medikal Bedah Edisi 12 volume 1*. Jakarta: EGC.
- Cao, S. S., & Lu, C. T. 2016. *Recent perspectives of breast cancer prognosis and predictive factors* (Review). *Oncology Letters*. Spandidos
- Davey, M.G., Hynes, S.O., Kerin, M.J., Miller, N., Lowery, A.J. 2021. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. *Cancers (Basel)*. Vol. 13 (17) :4455.
- Desen, Wan & Willie, J. 2008. *Buku Ajar Onkologi Klinis Edisi 2*. Jakarta : Balai Penerbit Fakultas Kedokteran Universitas Indonesia.
- Dharmawan MS, *et al.* 2020. Karakteristik kanker payudara di RSUP Sanglah Denpasar tahun 2015-2017. *Jurnal Medika Udayana*. Vol 9(7):56-59.
- European Society for Medical Oncology (ESMO). 2019. Early Breast Cancer: ESMO Clinical Practice Guidelines for diagnosis, Treatment and Follow-up.
- Falco, M. 2019. *Breast Cancer Basics*. American Cancer Society Inc.
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., *et al.* 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. Vol. 5(2):77-106.

- Hashmi A A, Hussain Z F, Faridi N, Khurshid A. Distribution of Ki-67 Proliferative Indices Among WHO Subtypes of Non-Hodgkin's Lymphoma: Association with other Clinical Parameters. *Asian Pacific Journal of Cancer Prevention*. 2014; 15: 248-65.
- Irawan, *et al.* 2008. Factors associated with bone metastasis in breast cancer: a preliminary study in an Indonesian population. *Acta Med Indones* ; 2008; 40(4): 178-80.
- Jezdic, S. 2018. *Breast Cancer: An ESMO Guide for Patients*. Europe: European Society for Medical Oncology.
- Joensuu, K., Leidenius, M., Kero, M., Andersson, L. C., Horwitz, K. B., & Heikkila, P. 2013. ER, PR, HER2, Ki-67 and cK5 in Early and Late Relapsing Breast cancer—Reduced CK5 Expression in Metastases. *Libertas Academica*, Vol. 7:23-24.
- Jung, M.P., Choi, S.B., Ahn, j.H., Go, J., Kim, J., Park, H.S., Kim, S.I., Park, B.W., Park, S. 2022. Ki-67 and Breast Cancer Prognosis: Does it Matter if Ki-67 Level is Examined Using Preoperative Biopsy or Postoperative Specimen?. *Breast Cancer Res Treat*. Vol 192(2):343-352.
- Kementrian Kesehatan Republik Indonesia (Kemenkes). 2022. *Kanker Payudara Paling Banyak di Indonesia, Kemenkes Targetkan Pemerataan Layanan Kesehatan*. <https://sehatnegeriku.kemkes.go.id/baca/umum/20220202/1639254/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan/>. Diakses Juli 2023.
- Kim S J, Choi C W. Ki-67 Expression is Predictive of Prognosis in Patients with Stage I/II Extranodal NK/T-cell Lymphoma, Nasal type. *Annals of Oncology*. 2017; 18: 1382–87
- Kurniawan A, *et al.* 2016. Cancer patient in Karawaci General Hospital. *Indonesian Journal of Cancer*. Vol 10(1):1-3
- Lheureux, S., Bruce, J. P., & Burnier, J. V. 2021. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. *International Journal of Gynecological Cancer*. Vol.31(1):21-30.
- Li, Z., Wei, H., Li, S., Wu, P., & Mao, X. 2022. The Role of Progesterone Receptors in Breast Cancer. *Drug Des Devel Ther*. Vol. 2022(16):305-314.
- Liao, G. S. Y., Foulkes, W. D., & Olivotto, I. A. (2019). The effect of germline BRCA mutations on breast cancer-specific mortality: A systematic review and meta-analysis. *Clinical Breast Cancer*. Vol.19(4):393-400.
- Lombardi A, Lazzeroni R, *et al.* 2021. The proper Ki-67 cut-off in hormone responsive breast cancer: a monoinstitutional analysis long term follow-up. *Breast cancer: targets and therapy*. Vol 13:213-217.
- Madani, S. H., Payandeh, M., Sadeghi, M., Motamed, H., Sadeghi, E. 2016. The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. *Indian J Med Paediatr Oncol*. Vol.37(2):95-9. doi: 10.4103/0971-5851.180136. PMID: 27168707; PMCID: PMC4854054.

- Moch, H., & Weichert, W. 2018. Definition and classification of immunohistochemical biomarkers in breast cancer. *Breast Care*. Vol. 13(4):252-258.
- Mohammed, A. A. 2019. Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study, *Annals of Medicine and Surgery*. Vol. 48(2019), 129-134. <https://doi.org/10.1016/j.amsu.2019.11.005>
- Mulyati H. 2015. Hubungan estrogen dengan kanker payudara. <http://www//medkes.com>
- Naajiyah R, *et al.* 2020. Studi tinjauan sistematik prevalensi infeksi pada pasien kanker payudara. *Jurnal Univesitas Gajah Mada*. 2020
- Narisuari IDAP, *et al.* 2016. Prevalensi dan gambaran karakteristik penderita kanker payudara di poliklinik bedah onkologi RSUP Sanglah, Bali, Indonesia 2016. *Intisari Sains Medis*. Vol 11(1)183-189.
- Nurhayati. 2018. Faktor-faktor Risiko Yang Berhubungan Dengan Kejadian Kanker Payudara Di RSUD Kota Padangsidempuan Tahun 2016. *Jurnal Warta Edisi* 56, 56, 1–11.
- Olivier M, Hollstein M, Hainaut P. 2010. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol*. Vol. 2(1):a001008
- PERABOI. 2020. *Panduan Penatalaksanaan Kanker Payudara*. Jakarta: PERABOI.
- Phan YC, *et al.* 2014. The statistics of breast cancer. *Journal of geriatric oncology*. Vol 5:525-580.
- Rakasiwi NPD, *et al.* 2019. Karakteristik kanker payudara dengan metastasis tulang tahun 2015-2017 di RSUP Sanglah Denpasar. *Jurnal Medika Udayana*. Vol 9(1):17-22.
- Rakha, E. A., Martin, S., Lee, A. H. S., Morgan, D., Pharoah, P. D. P., Hodi, Z., Macmillan, D., & Ellis, I. O. 2012. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. *Cancer*. Vol 118(15):3670–3680.
- Robbins, S., Aster, J., Perkins, J., Abbas, A. & Kumar, V., 2018. *Robbins basic pathology*. 10th ed. Chicago: Elsevier.
- Rustamadji, P. & Marisca, S. 2017. Karakteristik histopatologik dan imunolimpofoeitik kanker payudara di Rumah Sakit Cipto Mangunkusumo, Jakarta, Indonesia. *Journal Medicinus*. Vol 6(3): 66-72.
- Sabrina, Karina, *et al.* 2016. Korelasi ekspresi pemeriksaan imunohistokimia Ki-67 dengan grading karsinoma payudara di Instalasi Patologi Anatomi RSUD dr. Saiful Anwar Malang periode Januari 2013- Juni 2015. *Thesis Universitas Brawijaya*.
- Sanchez, N.A., Fisher, D., Krasinska, L. 2022. Physiological functions and roles in cancer of the proliferation marker Ki-67. *Journal of Cell Science*. Vol. 135 (11).

- Sanggam, B.H., Mulyadi, I.K., Artha, I.G.A. 2014. Ekspresi Ki-67 dan HER2/neu Berhubungan dengan Derajat Histopatologik Karsinoma Payudara Invasif *No Special Type* (NST). *Majalah Patologi*. Vol. 23 (2): 46-50.
- Sari PD, *et al.* 2016. Faktor - faktor yang berhubungan dengan kejadian kanker payudara di poliklinik onkologi RSUD Arifin achmad provinsi riau. *Jurnal Ilmu Kesehatan Masyarakat*, 05(2), 84–92.
- Soliman, N.A., Yussif, S.M. 2016. Ki-67 as a Prognostic Marker According to Breast Cancer Molecular Subtype. *Cancer Biol Med*. Vol. 13 (4) : 496-504.
- Song, B., Wang, L., Zhang, Y., Li, N., Dai, H., Xu, H., Cai, H., Yan, J. 2018. Combined Detection of HER2, Ki67, and GSTP1 Genes on the Diagnosis and Prognosis of Breast Cancer. *Cancer Biotherapy & Radiopharmaceuticals*. Vol. 34 (2) : 1-6.
- Stankov A, Rocha JEB, Silvio ANS, Ramirez MT, Ninova KS, Garcia AM. Prognostic Factors and Recurrence in Breast Cancer: Experience at the National Cancer Institute of Mexico. *International Scholarly Research Network Oncology Journal*. 2012; 1-5.
- Syapitri, H., Amila, Ns., Aritonang, J. 2021. *Buku Ajar Metodologi Penelitian Kesehatan*. Malang: Ahlimedia Press.
- Taneja, P., Maglic, D., Kai, F. 2010. Classical and Novel Prognostic Markers for Breast Cancer and Their Clinical Significance. *Clinical Medicine Insights: Oncology*. Vol. 4:15-34.
- Wang Y, Sun Y. 2018. Clinical implications of p53 alterations in breast cancer: prognostic and therapeutic relevance. *J Exp Clin Cancer Res*. Vol. 37(1):11.
- Went P. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score. *Journal Clinic Oncology*. 2016; 24:2472- 79.
- World Health Organizaton (WHO). 2021. *Breast Cancer: Early Diagnosis and Screening*. World Health Organization.